The USFDA has approved tropicamide and phenylephrine hydrochloride ocular spray, 1%/2.5%, for generating mydriasis during diagnostic vision procedures and in situations when short-term pupil dilation is sought. It is the first product using the fixed-dose combination of tropicamide and phenylephrine to be approved in the United States and is made to make office-based comprehensive eye exams more effective. Mechanism It is an alpha-1 adrenergic receptor agonist and anticholinergic fixed-combination ophthalmic spray.
It is a micro-mist that coats the eye by a specific dispenser and contains phenylephrine hydrochloride 2.5% and tropicamide 1%. The dispenser administers 0.008 mL of solution, which is less than 20% of that given with conventional eyedroppers, to reduce the overdose and exposure to drugs and preservatives. Faster than the ocular blink reflex, the solution reaches the ocular…
